Compare KZIA & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KZIA | SNES |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 14.5M |
| IPO Year | 1999 | 2016 |
| Metric | KZIA | SNES |
|---|---|---|
| Price | $13.05 | $2.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.00 | $10.00 |
| AVG Volume (30 Days) | ★ 1.9M | 80.6K |
| Earning Date | 12-26-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,199,108.00 | ★ $2,301,000.00 |
| Revenue This Year | N/A | $41.52 |
| Revenue Next Year | N/A | $77.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 39.37 |
| 52 Week Low | $2.86 | $1.30 |
| 52 Week High | $25.40 | $6.24 |
| Indicator | KZIA | SNES |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 47.61 |
| Support Level | $7.68 | $2.62 |
| Resistance Level | $11.13 | $2.91 |
| Average True Range (ATR) | 2.06 | 0.22 |
| MACD | 0.52 | 0.06 |
| Stochastic Oscillator | 69.83 | 95.38 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.